findmyKOL
Clinical trialNCT07219576RecruitingPhase 1/PHASE2Interventional

Retifanlimab and Ruxolitinib In Solid Malignancies

SponsorUniversity of California, San DiegoEnrollment40Non Small Cell Lung CarcinomaRenal Cell Carcinoma
View the registry record on ClinicalTrials.gov

Summary

The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • University of California, San Diego Moores Cancer Center

    La Jolla, California, United States

    Rana McKay, MD
    Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Retifanlimab →Ruxolitinib →
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
8 Jan 2026
Primary completion
31 Dec 2027
Completion
31 Dec 2029
Last update posted
13 Jan 2026
Registered enrollment
40
Registry id
NCT07219576
clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.